Alternative splicing in CKD

Journal of the American Society of Nephrology

Volumn 27, Issue 6, 2016, Pages 1596-1603

  Stevens, Megan ^a,b   Oltean, Sebastian ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; FIBRONECTIN; KLOTHO PROTEIN; PHOSPHOTRANSFERASE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ALTERNATIVE RNA SPLICING; CHRONIC KIDNEY FAILURE; GENE REGULATORY NETWORK; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; ANIMAL; GENETICS; MUTATION; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ALTERNATIVE SPLICING; ANIMALS; HUMANS; MUTATION; RENAL INSUFFICIENCY, CHRONIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84994553819     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015080908     Document Type: Review

References (68)

1. de Klerk E, 't Hoen PA: Alternative mRNA transcription, processing, and translation: insights from RNA sequencing. Trends Genet 31: 128-139, 2015
2. Matlin AJ, Clark F, Smith CW: Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 6: 386-398, 2005
3. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by highthroughput sequencing. Nat Genet 40: 1413-1415, 2008
4. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature 456: 470-476, 2008
5. Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, Slobodeniuc V, KutterC,Watt S,Colak R, KimT,Misquitta-Ali CM,WilsonMD, KimPM,OdomDT, Frey BJ, Blencowe BJ: The evolutionary landscape of alternative splicing in vertebrate species. Science 338: 1587-1593, 2012
6. Wang J, Zhang J, Li K, Zhao W, Cui Q: SpliceDisease database: linking RNA splicing and disease. Nucleic Acids Res 40: D1055-D1059, 2012
7. Oltean S, Bates DO: Hallmarks of alternative splicing in cancer. Oncogene 33: 5311-5318, 2014
8. Biamonti G, Catillo M, Pignataro D, Montecucco A, Ghigna C: The alternative splicing side of cancer. Semin Cell Dev Biol 32: 30-36, 2014
9. Chen J, Weiss WA: Alternative splicing in cancer: implications for biology and therapy. Oncogene 34: 1-14, 2015
10. Fu RH, Liu SP, Huang SJ, Chen HJ, Chen PR, Lin YH, Ho YC, Chang WL, Tsai CH, ShyuWC, Lin SZ: Aberrant alternative splicing events in Parkinson's disease. Cell Transplant 22: 653-661, 2013
11. Guo W, Schafer S, Greaser ML, Radke MH, Liss M, Govindarajan T, Maatz H, Schulz H, Li S, Parrish AM, Dauksaite V, Vakeel P, Klaassen S, Gerull B, Thierfelder L, Regitz-Zagrosek V,Hacker TA, Saupe KW, DecGW, Ellinor PT, MacRae CA, Spallek B, Fischer R, Perrot A, Ozcelik C, Saar K, Hubner N, Gotthardt M: RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med 18: 766-773, 2012
12. Gerold KD, Zheng P, Rainbow DB, Zernecke A, Wicker LS, Kissler S: The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 60: 1955-1963, 2011
13. Gohda T, Tanimoto M, Moon JY, Gotoh H, Aoki T, Matsumoto M, Shibata T, Ohsawa I, Funabiki K, Tomino Y: Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 81: 196-201, 2008
14. Will CL, Lührmann R: Spliceosome structure and function.Cold Spring Harb Perspect Biol 3: a003707, 2011
15. Zhou Z, Fu XD: Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma 122: 191-207, 2013
16. Fu XD, Ares M Jr: Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet 15: 689-701, 2014
17. Han SP, Tang YH, Smith R: Functional diversity of the hnRNPs: past, present and perspectives. BiochemJ 430: 379-392, 2010
18. Ule J, Ule A, Spencer J, Williams A, Hu JS, Cline M, Wang H, Clark T, Fraser C, Ruggiu M, Zeeberg BR, Kane D, Weinstein JN, Blume J, Darnell RB: Nova regulates brainspecific splicing to shape the synapse. Nat Genet 37: 844-852, 2005
19. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP: ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33: 591-601, 2009
20. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, Guo W, Xing Y, Carstens RP: An ESRP-regulated splicing programme is abrogated during the epithelialmesenchymal transition. EMBO J 29: 3286-3300, 2010
21. Yang J, Hung LH, Licht T, Kostin S, Looso M, Khrameeva E, Bindereif A, Schneider A, Braun T: RBM24 is a major regulator of muscle-specific alternative splicing. Dev Cell 31: 87-99, 2014
22. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, Hu Q,GhoshG, Adams JA, RosenfeldMG, Fu XD: The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 47: 422-433, 2012
23. Naro C, Sette C: Phosphorylation-mediated regulation of alternative splicing in cancer. Int J Cell Biol 2013: 151839, 2013
24. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003
25. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989
26. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62: 4123-4131, 2002
27. Harper SJ, Bates DO: VEGF-A splicing: The key to anti-angiogenic therapeutics? Nat Rev Cancer 8: 880-887, 2008
28. Cébe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, Manlius C, Wood J, Ballmer-Hofer K: A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 63: 2067-2077, 2006
29. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, Dvorak HF, Rosen S: Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 42: 1457-1461, 1992
30. Bevan HS, van den Akker NM, Qiu Y, Polman JA, Foster RR, Yem J, Nishikawa A, Satchell SC, Harper SJ, Gittenberger-de Groot AC, Bates DO: The alternatively spliced antiangiogenic family of VEGF isoforms VEGF(xxx) b in human kidney development. Nephron Physiol 110: 57-67, 2008
31. Cui TG, Foster RR, SaleemM, Mathieson PW, Gillatt DA, Bates DO, Harper SJ: Differentiated human podocytes endogenously express an inhibitory isoformof vascular endothelial growth factor (VEGF165b) mRNA and protein. Am J Physiol Renal Physiol 286: F767-F773, 2004
32. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA: Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 43: 636-650, 2004
33. Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004
34. Martini S, Nair V, Keller BJ, Eichinger F, Hawkins JJ, Randolph A, Böger CA, Gadegbeku CA, Fox CS, Cohen CD, Kretzler M; European Renal cDNA Bank; C-PROBE Cohort; CKDGen Consortium: Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol 25: 2559-2572, 2014
35. Oltean S, Qiu Y, Ferguson JK, Stevens M, Neal C, Russell A, Kaura A, Arkill KP, Harris K, Symonds C, Lacey K, Wijeyaratne L, Gammons M, Wylie E, Hulse RP, Alsop C, Cope G, Damodaran G, Betteridge KB, Ramnath R, Satchell SC, Foster RR, Ballmer-Hofer K, Donaldson LF, Barratt J, Baelde HJ, Harper SJ, Bates DO, Salmon AH: Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J Am Soc Nephrol 26: 1889-1904, 2015
36. Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25-35, 2001
37. Maynard SE,Min JY,Merchan J, LimKH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658, 2003
38. Javanmard SH, Hasanpour Z, Abbaspoor Z, Naderian GA, Jahanmard M: Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients. J Res Med Sci 17: 1124-1127, 2012
39. Belgore FM, Blann AD, Li-Saw-Hee FL, BeeversDG, LipGY: Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87: 805-807, A9, 2001
40. DiMarco GS, Reuter S,Hillebrand U, Amler S, König M, Larger E, Oberleithner H, Brand E, Pavenstädt H, Brand M: The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 20: 2235-2245, 2009
41. Jin J, Sison K, Li C, Tian R,WnukM, Sung HK, JeanssonM, Zhang C, Tucholska M, JonesN, Kerjaschki D, Shibuya M, Fantus IG, Nagy A, Gerber HP, Ferrara N, Pawson T, Quaggin SE: Soluble FLT1 binds lipidmicrodomains in podocytes to control cell morphology and glomerular barrier function. Cell 151: 384-399, 2012
42. Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H: Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy. PLoS One 9: e101779, 2014
43. HuMC, Kuro-oM,MoeOW: Secreted klotho and chronic kidney disease. Adv Exp Med Biol 728: 126-157, 2012
44. Hu MC, Kuro-o M, Moe OW: Klotho and chronic kidney disease. Contrib Nephrol 180: 47-63, 2013
45. Lee EY, Kim SS, Lee JS, KimIJ, Song SH, Cha SK, Park KS, Kang JS, Chung CH: Soluble a-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes. PLoS One 9: e102984, 2014
46. Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadhani R: Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS One 5: e9246, 2010
47. ArcasoyMO, Jiang X, Haroon ZA: Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 307: 999-1007, 2003
48. Baynes RD, Reddy GK, Shih YJ, Skikne BS, Cook JD: Serum form of the erythropoietin receptor identified by a sequence-specific peptide antibody. Blood 82: 2088-2095, 1993
49. Van Vliet A, Baelde HJ, Vleming LJ, de Heer E, Bruijn JA: Distribution of fibronectin isoforms in human renal disease. J Pathol 193: 256-262, 2001
50. Baelde HJ, Eikmans M, van Vliet AI, Bergijk EC, de Heer E, Bruijn JA: Alternatively spliced isoforms of fibronectin in immunemediated glomerulosclerosis: The role of TGFbeta and IL-4. J Pathol 204: 248-257, 2004
51. Phanish MK, Heidebrecht F, Nabi ME, Shah N, Niculescu-Duvaz I, Dockrell ME: The regulation of TGFb1 induced fibronectin EDA exon alternative splicing in human renal proximal tubule epithelial cells.JCell Physiol 230: 286-295, 2015
52. Viedt C, Bürger A, Hänsch GM: Fibronectin synthesis in tubular epithelial cells: upregulation of the EDA splice variant by transforming growth factor beta. Kidney Int 48: 1810-1817, 1995
53. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA: A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 105: 20333-20338, 2008
54. Ho TH, Charlet-B N, Poulos MG, Singh G, Swanson MS, Cooper TA: Muscleblind proteins regulate alternative splicing. EMBO J 23: 3103-3112, 2004
55. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA: Expanded CTG repeats within the DMPK 39 UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A 105: 2646-2651, 2008
56. Bullock N, Potts J, Simpkin AJ, Koupparis A, Harper SJ,Oxley J, Oltean S: Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion [published online ahead of print October 23, 15]. J Clin Pathol doi:10.1136/jclinpath-2015-203125
57. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S, Eymin B: Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS One 7: e46539, 2012
58. Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO: SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem Soc Trans 40: 831-835, 2012
59. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-ZadehM,Welsh GI, CheungMK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR: WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20: 768-780, 2011
60. Singh RK, Cooper TA: Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18: 472-482, 2012
61. Chang JG, Yang DM, Chang WH, Chow LP, Chan WL, Lin HH, Huang HD, Chang YS, Hung CH, Yang WK: Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells. PLoS One 6: e18643, 2011
62. ChangWH, Liu TC, YangWK, Lee CC, Lin YH, Chen TY, Chang JG: Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. Cancer Res 71: 383-392, 2011
63. Gammons MV, Federov O, Ivison D, Du C, Clark TL, Hopkins C, Hagiwara M, Dick AD, Cox R, Harper SJ, Hancox JC, Knapp S, Bates DO: Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci 54: 6052-6062, 2013
64. Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO: Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer 111: 477-485, 2014
65. Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S: Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 34: 4311-4319, 2015
66. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111: 1487-1491, 2005
67. Pan S, Chen HH, Dickey DM, Boerrigter G, LeeC, Kleppe LS,Hall JL, LermanA,Redfield MM, Potter LR, Burnett JC Jr, Simari RD: Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A 106: 11282-11287, 2009
68. Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG, Chen G, Zhang N, Gabbeta V, Vazirani P, Bhattacharyya A, Furia B, Risher N, Sheedy J, Kong R, Ma J, Turpoff A, Lee CS, Zhang X, Moon YC, Trifillis P, Welch EM, Colacino JM, Babiak J, Almstead NG, Peltz SW, Eng LA, Chen KS, Mull JL, Lynes MS, Rubin LL, Fontoura P, Santarelli L, Haehnke D, McCarthy KD, Schmucki R, Ebeling M, Sivaramakrishnan M, Ko CP, Paushkin SV, Ratni H, Gerlach I, Ghosh A, Metzger F: Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345: 688-693, 2014